Antimicrobial Resistance: Preventable or Inevitable?

Aksoy, Duygu Yazgan; Tanrıöver, Mine Durusu; Ünal, Serhat

doi:10.1007/978-0-387-70841-6_8

Cited by 2 publications

(1 citation statement)

References 149 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…aureus (MRSA), which are resistant not only to all β‐lactams, but also to the other main antibiotic classes, has resulted in an increased use of glycopeptide antibiotics, i.e., vancomycin and teicoplanin. Unfortunately, VRE were detected in 1986, both in France and the UK, and multidrug‐resistant strains of enterococci are now encountered throughout Europe and the USA [2–4]. Within 1 year of their initial detection, resistant strains were associated with infections in the USA, and they accounted for 26% of isolates of enterococci from blood in the USA by the year 2000.…”

Section: Introductionmentioning

confidence: 99%

New antimicrobial agents for the treatment of Gram-positive bacterial infections

Aksoy

Ünal

2008

Clinical Microbiology and Infection

View full text Add to dashboard Cite

Since the 1970s, resistance to antimicrobial agents has become an escalating problem. In the last 25 years, treatment of infections caused by Gram-positive bacteria has been more problematical than ever, with infections being caused by multidrug-resistant organisms, particularly methicillin-resistant staphylococci, penicillin- and erythromycin-resistant pneumococci, and vancomycin-resistant enterococci. There is a continuing effort in the pharmaceutical industry to develop new antimicrobial agents for the treatment of resistant infections. Linezolid, quinupristin-dalfopristin, daptomycin, tigecyline, new glycopeptides and ceftobiprole are the main agents recently introduced or under clinical development. This review summarises their major properties, the results of recent studies with these agents, and future treatment possibilities.

show abstract

Section: Introductionmentioning

confidence: 99%